Table 6.
BC administration in critically ill patients.
| Authors | Study Design | Population Number Groups Gender Mean Age |
Intervention Matrix |
TG Size Dosage Frequency Duration |
Control Matrix |
CG Size Dosage Frequency Duration |
Endpoints/Data Collection Tools | Adverse Events | Results | OCEBM | EPHPP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Eslamian, G., et al. (2019) [55] | RCT, DB, PC | ICU patients n = 70; mean age 62 ys Colostrum (n = 35) vs. Placebo (n = 35) n = 8 not included in the analysis |
Neovite ® (London, UK). | TG (n = 32): BC 20 g/day + enteral feeding for 10 days | ENTERA Meal®; (Tehran, Iran) | CG (n = 30): Isocaloric maltodextrin + enteral feeding for 10 days | PE: Intestinal permeability (plasmatic endotoxin and zonulin) SE: mortality, LOS, GI complications |
No AEs | ↓ Plasmatic endotoxin and zonulin concentrations at day 10. ↓ Diarrhea No significant differences in other comparisons |
Level 2 | 1 |
OCEBM = Oxford Centre for Evidence Based Medicine; EPHPP = Effective Public Health Practice Project, RCT = Randomized Controlled Trial; DB = Double Blind; PC = Placebo Controlled; ICU = Intensive Care Unit; ys = years; TG = Treatment Group; BC = Bovine Colostrum; CG = Control Group; WP = Whey Protein; PE = Primary Endpoint; SE = Secondary Endpoint; LOS = Length of Stay; GI = Gastrointestinal; AEs = Adverse Events. Symbol: ↓ = decreased.